NKG2A is predominantly co-expressed with IL-2Rβγ in both human and murine CD8+ T and NK cells, indicating its potential as a novel target for delivery of IL-2Rβγ agonists for tumor immunotherapy. Here, CD8A is linked to neoplasm.